FDA OKs First Gene Therapy for Spinal Muscular Atrophy

A single, one-time infusion of onasemnogene abeparvovec-xioi (Zolgensma) can minimize the progression of SMA and improve survival in children younger than age 2 years — and will cost over $2 million.
FDA Approvals

Source link

Related posts

How soon is soon enough to learn you have Alzheimer’s?


Golgin A4 in CSF and granulovacuolar degenerations of patients with Alzheimer disease


Asthma and Allergic Rhinitis May Be Risk Factors for Migraine in Adolescents


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy